Comparison of dydrogesterone and oral contraceptive pills in the treatment of endometrial polyps

Comparison of the efficacy of dydrogesterone versus oral contraceptive pills in the treatment of endometrial polyps smaller than 1.5 cm: A randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260423069139N1

Enrollment

Registered

2026-05-28

Start date

2026-06-22

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial polyp. Polyp of corpus uteri

Interventions

Intervention 1: Intervention group: Participants in the intervention group will receive Dydrogesterone 10 mg oral tablets (Manufactured by Iran Hormone Pharmaceutical Co.), twice daily, from day 15 to

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Premenopausal women aged 18 to 40 years Diagnosis of endometrial polyp smaller than 1.5 cm confirmed by transvaginal ultrasound Having abnormal uterine bleeding (AUB) for less than 6 months Providing written informed consent

Exclusion criteria

Exclusion criteria: Severe underlying diseases limiting hormonal therapy (e.g., uncontrolled diabetes, cardiovascular disease, thromboembolic disease) History of endometrial hyperplasia or atypical lesions Hormonal treatment within the previous 3 months Pregnancy or lactation Known allergy to dydrogesterone or oral contraceptive pill (OCP)

Design outcomes

Primary

Measure	Time frame
Endometrial polyp size. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Transvaginal ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolnar Hematyar

Shahid Beheshti University of Medical Sciences

Hematyargolnar@gmail.com+98 21 7343 3000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026